Raymond James raised the firm’s price target on 89bio to $50 from $25 and keeps a Strong Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ETNB:
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio Surges after Positive Topline Results
- 89bio price target raised to $45 from $34 at Cantor Fitzgerald
- 89bio NASH data show high statistical significance, says Cantor Fitzgerald
- 89bio’s pegozafermin trial statistically significant in critical histology